{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-023942","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2025-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.822467+00:00","generated_at":"2026-05-16T18:52:00.437671+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Dermata terminates Villani license, pivots to OTC skin care","bullets":["Terminated license agreement with Villani Inc.; effective 90 days after Nov 17, 2025 notice.","Eliminates future milestone payments of up to $40.5M and single-digit royalties.","Strategic shift: will commercialize OTC skin care; withdrew XYNGARI IND.","License covered exclusive rights to sponge-based products for skin disease treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-023942","json":"https://secwatch.observer/filing/0001493152-25-023942.json","markdown":"https://secwatch.observer/filing/0001493152-25-023942.md","text":"https://secwatch.observer/filing/0001493152-25-023942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225023942/0001493152-25-023942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225023942/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:52:00.437671+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}